XNCR at a glance
Xencor Inc (XNCR, SEC CIK 1326732) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and Form 4 insider filings as recently as July 8, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Xencor Inc (XNCR) reported revenue of $125.6 million (up 13.7% from FY2024) and a net loss of $91.9 million. Diluted EPS was -$1.24.
- As of June 30, 2026, 31 institutional investment managers tracked by SignalX reported holding Xencor Inc (XNCR) shares worth $585.8 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Feigal Ellen on June 18, 2026 of 6,843 shares at $13.06 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $125.6M
- +13.7% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 31 funds
- $585.8M · +1 vs prior quarter
- Latest 8-K
- Aug 5, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Clinical-stage biopharma developing engineered XmAb antibody therapeutics targeting cancer and autoimmune diseases with modular bispecific Fc domain technology
- New product emphasis: XmAb412, a bispecific antibody targeting TL1A and IL23p19 in autoimmune diseases, first-in-human studies planned for 2026
- Strategic shift: Prioritization of T cell-engaging bispecific antibody programs in oncology, expanding XmAb 2+1 bispecific format applications in solid tumors
- Quantitative metric: Phase 1 XmAb819 RCC study enrolled 69 patients, 25% partial response rate, 70% disease control rate; XmAb942 Phase 2b initiated in ulcerative colitis
- Noteworthy fact: Collaboration revenues include $70.1M royalties from Alexion’s Ultomiris and $10.2M from Incyte’s Monjuvi in 2025, highlighting growing partner-generated income
Risk Factors
- Regulatory risk from FDA approvals with no products yet approved using XmAb platform, uncertain commercial viability of candidates
- Geopolitical/macro risk from California concentration; wildfires or earthquakes could disrupt operations and third-party supply continuity
- Supply chain vulnerability relying on third-party manufacturers, contract research organizations, and collaborators for manufacturing and clinical execution
- Competitive risk from other biotech/pharma firms with new products and technologies impacting market position and stock volatility
- Financial risk of significant net loss $91.9M in 2025, accumulated deficit $796.0M, requiring additional financing beyond $610.8M cash reserves to fund operations through 2028
Management Discussion & Analysis
- Revenue $125.6M in 2025, up $15.1M YoY from $110.5M in 2024, driven by Alexion and Incyte license agreements
- Operating loss $177.5M in 2025, nearly flat vs $178.4M in 2024, representing an operating margin of -141.3% vs -161.4%
- Best segment Royalties $80.3M in 2025, up $12.8M YoY; worst segment License revenues $0 in 2025 vs $8.5M in 2024
- Management emphasizes disciplined portfolio management and clinical data-driven strategy; no explicit forward guidance stated
AI summary of the XNCR 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- No profitability or margin percentages disclosed in provided excerpt
- Portfolio spanning early- and mid-stage clinical programs, with three marketed medicines using XmAb technologies
- Disciplined portfolio management: advancing, partnering, or discontinuing programs based on clinical data and priorities
- No cash, operating cash flow, capital deployment, or updated guidance details disclosed in provided excerpt
Risk Factors
- Risk factors section not provided; supplied text covers Items 2–6 and signatures
- Trading-plan risk: Chief Scientific Officer’s arrangement covering 41,883 shares terminated June 23, 2026 before any sales
- Executive compensation change: Executive Severance Policy dated April 23, 2026
AI summary of the XNCR 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026
- Press release in Exhibit 99.1 contains the financial results and investor-relevant metrics
Item 7.01: Regulation FD Disclosure
- Settlement Agreement with Alexion announced July 29, 2026
- Exhibit 99.1 contains the press release and substantive settlement terms
Item 2.02: Results of Operations and Financial Condition
- Cash runway expected through 2028, supporting continued R&D programs and operations
- Forward-looking liquidity outlook, but no current cash balance or financial results disclosed
Item 1.01: Entry into a Material Definitive Agreement
- $105 million settlement with Alexion resolves dispute over U.S. Ultomiris royalty obligations
- $52.5 million payment expected August 2026, with remaining $52.5 million due within 14 days after July 29, 2027
Item 5.07: Submission of Matters to a Vote of Security Holders
- 2026 annual meeting reached 86.26% participation, with 63,939,410 shares represented
- All nine director nominees elected through the 2027 annual meeting, with 60,377,318–63,181,996 votes for
AI summaries of XNCR 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for XNCR
Don't miss the next XNCR filing
- Alerts as it files. A push when XNCR files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut XNCR, by share count.
- Ask anything. An AI agent that reads every XNCR filing and answers with sources.
XNCR alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Feigal Ellen | Sell | Jun 18, 2026 | 6,843 | $13.06 |
| SIMPSON TODD E | A | Jun 16, 2026 | 10,302 | - |
| Klencke Barbara | A | Jun 16, 2026 | 20,604 | - |
| Deshaies Raymond Joseph | A | Jun 16, 2026 | 10,302 | - |
| Deshaies Raymond Joseph | A | Jun 16, 2026 | 20,604 | - |
| Klencke Barbara | A | Jun 16, 2026 | 10,302 | - |
| SIMPSON TODD E | A | Jun 16, 2026 | 20,604 | - |
| Feigal Ellen | A | Jun 16, 2026 | 10,302 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $110.5M | $125.6M |
| Operating Income | - | -$178.4M | -$177.5M |
| Net Income | -$126.1M | -$232.6M | -$91.9M |
| Op. Margin | - | -161.5% | -141.4% |
| Net Margin | - | -210.5% | -73.2% |
| Balance Sheet | |||
| Total Assets | $952.7M | $951.9M | $875.5M |
| Equity | - | $677.6M | $635.6M |
| ROE | - | -34.3% | -14.5% |
| Per Share | |||
| EPS | $-2.08 | $-3.58 | $-1.24 |
| Cash Flow | |||
| Operating CF | - | -$202.2M | -$135.1M |
| CapEx | $18.4M | $6.1M | $3.1M |
Source: XBRL data in Xencor Inc (XNCR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate XNCR share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 31 | $585.8M |
| Q1 2026 | 30 | $418.9M |
| Q4 2025 | 28 | $519.8M |
| Q3 2025 | 29 | $403.0M |
| Q2 2025 | 29 | $292.6M |
| Q1 2025 | 26 | $208.6M |
| Q4 2024 | 19 | $380.9M |
| Q3 2024 | 19 | $207.4M |
- T. Rowe Price Group+796.0K (+51%)
- BlackRock+615.3K (+5%)
- State Street Corp+602.0K (+14%)
- AQR Capital Management+321.4K (+198%)
- Millennium Management+243.9K (+40%)
- Vanguard Portfolio Management LLC−1.28M (-37%)
- Dimensional Fund Advisors−283.8K (-22%)
- Citadel Advisors LLC−186.9K (-49%)
- JPMorgan Chase & Co−34.8K (-17%)
- Bank of America Corp−5.7K (-2%)
- D.E. Shaw & Co+50.5K
- Allstate+10.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 211 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
XNCR filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| SC 13G | Jul 31, 2026 | - | - | |
| 8-K | Jul 29, 2026 | - | Analysis | - |
| 4 | Jul 8, 2026 | - | - | - |
| 4 | Jul 8, 2026 | - | - | - |
| 4 | Jul 8, 2026 | - | - | - |
| 4 | Jul 8, 2026 | - | - | - |
| 4 | Jul 8, 2026 | - | - | - |
| 4 | Jul 8, 2026 | - | - | - |
| 4 | Jul 8, 2026 | - | - | - |
| 4 | Jul 8, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 8-K | Jun 18, 2026 | - | Analysis | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 8-K | May 6, 2026 | - | Analysis | |
| 10-Q | May 6, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 5, 2026 | - | Analysis | - |
| 8-K | Apr 27, 2026 | - | Analysis | - |
| 4 | Apr 13, 2026 | - | - | - |
| SC 13G | Mar 30, 2026 | - | - | |
| 4 | Mar 9, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
XNCR SEC filings: frequently asked questions
Which institutions hold XNCR stock?
As of June 30, 2026, the largest Xencor Inc (XNCR) holders among the 13F filers tracked by SignalX were BlackRock ($219.8 million), State Street Corp ($79.8 million), Vanguard Capital Management LLC ($52.8 million), T. Rowe Price Group ($37.9 million), Vanguard Portfolio Management LLC ($35.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was XNCR's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Xencor Inc (XNCR) reported revenue of $125.6 million (up 13.7% from FY2024) and a net loss of $91.9 million. Diluted EPS was -$1.24. The figures come from the XBRL data in the 10-K.
What are the main risks in XNCR's latest 10-K?
In the 10-K filed February 25, 2026, Xencor Inc (XNCR) flagged: Regulatory risk from FDA approvals with no products yet approved using XmAb platform, uncertain commercial viability of candidates. Geopolitical/macro risk from California concentration; wildfires or earthquakes could disrupt operations and third-party supply continuity. (AI summary of the Risk Factors section.)
What did XNCR report in its latest 8-K?
Xencor Inc (XNCR) filed an 8-K on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 2026 results for quarter ended June 30, 2026.
What are the latest XNCR SEC filings?
Xencor Inc (XNCR) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and a Form 4 insider filing on July 8, 2026.
What is XNCR's SEC CIK number?
Xencor Inc (XNCR)'s SEC Central Index Key (CIK) is 1326732. EDGAR lists every XNCR filing under that number.
Ask anything about XNCR
The research agent reads XNCR's filings, financials, insider trades and 13F holders, then answers with sources.